New Stem Cell Treatment Being Evaluated for Critically Ill Bone Marrow Transplant Patients; Osiris Launches a Phase II Clinical Trial for Severe Graft vs Host Disease
Osiris Therapeutics, Inc. announced today that it has received clearance from the United States Food and Drug Administration (FDA) to conduct a Phase II trial to evaluate the safety and effectiveness of its lead investigational stem cell drug, Prochymal, for the rescue of patients with the most severe form of acute graft vs. host disease (GVHD).
Article
Renal Cell Carcinoma, Trovax Phase II Results Encouraging
The data show that TroVax is safe and well tolerated in this patient group and that the product induces a strong anti-tumour immune response against the 5T4 tumour antigen.
Article
GE Healthcare and ThermoGenesis Announce Worldwide Distribution Agreement and R&D Collaboration
The companies will jointly present the AXP AutoXpress Platform, a closed and automated system for harvesting mononuclear cells (MNC) from cord blood, at the AABB Annual Meeting in Seattle, Washington on October 17th and 18th.
Article
Cryo-Cell Affiliate Awarded Grants for Cell Therapy Research: Saneron CCEL to Evaluate Cord Blood Cells for Cardiac Therapy
Cryo-Cell International, Inc. (OTC Bulletin Board: CCEL – News; the “Company”) announced today that its affiliate, Saneron CCEL Therapeutics, Inc. (“Saneron CCEL”), has been awarded two grants to study the effects of cord blood stem cells for the treatment of myocardial infarction, commonly known as heart attack.
Article
Targeted Genetics Initiates Next Clinical Trial of tgAAC94 in Inflammatory Arthritis
tgAAC94 utilizes Targeted Genetics’ Adeno-Associated Viral (AAV) vector technology to deliver a DNA sequence encoding an inhibitor of TNF-alpha, a potent proinflammatory cytokine that plays a major role in inflammatory arthritis.
Article
Inovio Study Results of Gene-Based Therapies for HIV and Vascular Disease Published in Scientific Journals; Articles Published in Collaboration with Boehringer Ingelheim and Chiron Corporation
Inovio Biomedical Corporation (AMEX:INO), a late stage developer of oncology and other therapies using electroporation to deliver drugs and nucleic acids, announced today that two articles presenting study results relating to gene-based therapies for HIV and vascular disease were published in peer-reviewed scientific journals in September 2005.
Article
Invitrogen Wins Appeals Court Decision against Stratagene; Stratagene’s Competent Cell Products Found to Infringe Invitrogen’s Patent
On appeal from a decision by the U.S. District Court for the Western District of Texas, the U.S. Court of Appeals for the Federal Circuit found that substantially all of the chemically competent cell products sold by Stratagene infringed Invitrogen’s patent. In the decision, the Court of Appeals remanded the case to the district court for further proceedings.
Article
VIRxSYS Completes $30 Million Financing
VIRxSYS Corporation, a privately held company developing genetic therapies for HIV and cancer, announced the final closing of their latest financing round.
Article
Cognate Therapeutics, Inc. Announces Appointment Of Brandon J. Price As Chief Executive Officer
Cognate Therapeutics, Inc. today announced the appointment of Brandon J. Price as Chief Executive Officer and member of the Board of Directors, effective September 12, 2005.
Article
BioE Appoints Vice President of Corporate Development; Dr. Sarah Haecker Brings Significant Bench-to-Business Life Sciences Experience and Strong Leadership, Management Skills to BioE
BioE(R), Inc., a biomedical company providing enabling non-embryonic, human stem cells, announced today it appointed Sarah Haecker, Ph.D. vice president of corporate development.
Article
Leading US Neuroscientist appointed Chief Scientific Officer of LCT BioPharma
LCT announced that Dwaine F. Emerich has been appointed Chief Scientific Officer of LCT BioPharma Inc.
Article
Innate Pharma Completes Its Management Team with the Recruitment of Dr. Patrick Squiban as Chief Medical Officer
Innate Pharma, a French biotechnology company focused on cancer immunotherapy through the manipulation of the innate immune system, announced today the appointment of Patrick Squiban M.D. as Chief Medical Officer.
Article
BioE Selected as a 2005 Tekne Award Finalist; Annual Award Program Honors Companies and Individuals Who Have Shown Superior Technology Innovation and Leadership in Minnesota
BioE(R), Inc., a biomedical company providing enabling non-embryonic, human stem cells, announced today the Minnesota High Tech Association (MHTA) and Minnesota Technology, Inc. (MTI), in partnership with Medical Alley/MNBio, selected it as a 2005 Tekne Award finalist in the emerging biotechnology company category.
Article
Iasis Software Releases Donor and Collections Management Module
Iasis Software this week released I-Collect, our comprehensive solution for managing the collections process and donor information.
Article